NEW YORK (GenomeWeb News) – Maven Biotechnologies is seeking a buyer for its label-free detection and imaging technology.
The technology called LFIRE is a method for detection and ellipsometry reflection and provides enhanced, high-content, label-free detection and imaging and high-capacity screening. Today, BioMed Transition Partners announced Maven Bio has retained its services to help find a buyer for the technology.
Monrovia, Calif.-based life science tools company Maven Bio said on its website that LFIRE measures biomolecular interactions in a microarray or well-plate format, and added that as a real-time system, it provides information about a sample before and after equilibrium, which is required "for increasing the dynamic range of concentration measurements, optimizing biological assays, and analyzing kinetic activity critical to drug research."
The system, which can be used for molecular and cell-based assays, is currently in the optimization stage of development and is near market commercialization for research applications, BioMed Transition said.
The technology has applications in research, development, and quality control in academic laboratories, pharmaceutical companies, clinical diagnostics, point-of-care diagnostics, and the animal health and food and beverage markets, the New York-based biomedical management advisory firm added. BioMed Transition is an affiliate of The Channel Group, an investment, development, and management firm.